

1 **EVALUATION OF THE SAFETY AND TOLERABILITY OF EXOGENOUS**
2 **KETOSIS INDUCED BY ORALLY ADMINISTERED FREE BETA-**
3 **HYDROXYBUTYRATE IN HEALTHY ADULT SUBJECTS**

4

5 Lisa Isabel Pimentel-Suarez^{1,2} and Luis Adrian Soto-Mota^{1,2*}

6

7 1 *Metabolic Diseases Research Unit. National Institute of Medical Sciences and*
8 *Nutrition Salvador Zubiran. Mexico City, Mexico.*

9 2 *Tecnologico de Monterrey. School of Medicine. Mexico City, Mexico.*

10

11 * *Correspondence: adrian.sotom@incmnsz.mx; 5487 0900 ext. 6321*

12

13

14 **ABSTRACT**

15 Beta-hydroxybutyrate (D-BHB) is a metabolite with intrinsic signalling activity that
16 has gained attention as a potentially clinically useful supplement. There are available
17 supplements for inducing ketosis: ketone salts, ketone esters, and medium-chain triglycerides.
18 Even when all of them raise the beta-hydroxybutyrate in the blood and all are safe and well
19 tolerated, they significantly differ in their safety profile, their palatability, and their price. A
20 fourth and potentially interesting option is to use biologically identical beta-hydroxybutyrate,
21 while it is already commercially available in the United States (American Ketone LLC) and
22 Greater China (MedPHA Ltd). However, its safety and tolerability had not yet been
23 documented in the scientific literature. We evaluated the safety and tolerability of orally
24 administered Free D-BHB in a gender and age-balanced sample of 24 asymptomatic and
25 overtly healthy adults. No participant showed acid-base abnormalities or electrolyte
26 abnormalities. Secondary symptoms were reported after only 6.2% of all drink takes and
27 none of the reports described the symptom as “severe”. The most frequently reported
28 secondary effects (19/720 or 2.6%) were gastrointestinal discomfort, headache (7/720 or 1%),
29 and loss of appetite (7/720 or 1%). No correlation between weight-adjusted dose and
30 frequency of secondary symptoms was observed. Free D-BHB was a safe and well-tolerated
31 intervention for inducing sustained exogenous ketosis. Being bio-identical, salt-free, and
32 lacking intermediate metabolites, this form of supplementation could have a larger safety
33 spectrum than salt or alcohol-based exogenous ketones. More research is warranted to assess
34 its clinical efficacy in those clinical scenarios in which achieving ketosis rapidly could be
35 beneficial.

36

37 **Keywords:** Exogenous ketosis; beta-hydroxybutyrate; safety; tolerability; ketone bodies

38 **KEY MESSAGES**

39

40

41 **What is already known on this topic**

- 42 - Ketogenic supplements could be useful therapeutic tools in certain time-sensitive
43 circumstances. A previously unexplored but attractive option is using bio-identical D-
44 BHB.

45 **What this study adds**

- 46 - Diluted Free D-BHB is a safe and well-tolerated intervention for inducing sustained
47 exogenous ketosis.

48 **How this study might affect research, practice, or policy**

- 49 - Being bio-identical, salt-free, further research is warranted on the potential clinical uses
50 of Free-BHB.

51

52 INTRODUCTION

53 Several ketogenic interventions have shown benefits in a wide variety of clinical
54 scenarios [1–5]. Ketosis can be induced in different ways: by 72 hours of fasting [6], with a
55 carbohydrate-restricted [7] diet, and within minutes using supplements [8]. While
56 endogenous ketosis interventions have proven useful in many illnesses such as diabetes [2],
57 psychiatric illnesses [9], migraine, [10], and cognitive decline [11], in some time-sensitive
58 clinical scenarios where ketosis could be beneficial (for example, heart failure [12] or sepsis
59 [13]) endogenous ketosis is impractical as patients cannot wait 72 hours for achieving a
60 physiologically relevant production.

61 Beta-hydroxybutyrate (D-BHB) is a metabolite with intrinsic signalling activity [14],
62 therefore, it has gained attention as a potentially clinically useful supplement. There are three
63 thoroughly studied ketone supplements for inducing ketosis: ketone salts [15–17], ketone
64 esters [18], and medium-chain triglycerides [19]. Even when they all raise the beta-
65 hydroxybutyrate in the blood and all are safe and well tolerated, they significantly differ in
66 their safety profile, palatability, and price [8,20].

67 A fourth and potentially interesting option is to use biologically identical (D-Beta-
68 hydroxybutyrate). Being salt-free and having no intermediate metabolites or precursors, it
69 could have a broader clinical reach than previous ketone supplements (e.g. , patients with
70 mineral load restrictions such as those living with heart failure [12] or chronic kidney disease
71 [21,22]). While it is already commercially available in the United States (American Ketone
72 LLC) and Greater China (MedPHA Ltd), its safety and tolerability had not yet been
73 documented in the scientific literature. In this work, we evaluated the safety and tolerability
74 of Free D-BHB as a ketogenic supplement in healthy adults.

75

76 MATERIALS AND METHODS

77 This study was pre-registered in ClinicalTrials.gov on October 22nd, 2022, with the
78 identifier NCT05584371. Ethical approval was obtained from the Ethics Committee of the
79 National Institute of Medical Sciences and Nutrition Salvador Zubirán with the file code
80 UIE-4275-22-23-1 on September 22nd, 2022. The study workflow can be observed in Figure
81 1.

82 A gender and age-balanced sample of asymptomatic adults (most of them, healthcare
83 workers) without illnesses that caused acid-base imbalances were recruited and asked to
84 ingest 10 grams of beta-hydroxybutyrate, diluted in one litre of water and sweetened with a
85 sugar substitute derived from the stevia plant already embedded in the preparation, every
86 morning between 9:00 and 11:00 for four weeks. Women of childbearing age were recruited
87 only if using a long-term method of contraception including any form of hormonal
88 contraception and intrauterine devices. The exclusion criteria included adults on a ketogenic
89 diet, carbohydrate-restricted diet, or intermittent fasting.

90 The exogenous ketones used in our study were provided by a joint donation from
91 American Ketone LLC and MedPHA Ltd. This bio-identical D-BHB is produced with the
92 acid hydrolysis of Poly-3Hydroxy-Butyrate [23] and is available in 60 ml bottles with 10g of
93 free D-BHB each. Participants were instructed to dilute their content in 1 litre of water before
94 consuming it.

95 As previously used in other studies on ketone supplement studies [18], the frequency
96 and severity of symptoms (mild, moderate, severe) were assessed every two weeks with a
97 self-administered open questionnaire to avoid priming positive and negative symptom reports
98 and the intervention adherence was corroborated with qualitative urinary ketone strips
99 (calculated as the proportion of urinary ketone strips with detectable acetoacetate). Venous

100 blood gases were analysed at the baseline, 2 and 4 weeks later to rule out acid-base disorders.
101 All blood samples were handled and analysed at the central lab of the National Institute of
102 Medical Sciences and Nutrition Salvador Zubiran adhering to their internationally certified
103 standard operating procedures.

104 Being hemodynamically stable, and consistent with previous studies, venous blood
105 samples were preferred over arterial ones. Since acid-base analysis assumes arterial values,
106 all acid-base variables were therefore “arterialized” by adding 0.04 to the measured pH and
107 subtracting 5 from the measured pCO₂ [24]. Because of Mexico City’s altitude, the normal
108 range for CO₂ is different than for most places in the world (30.2 ± 3.4 mmHg) [25].

109 Data were analysed using R version 4.0.3 with R-Studio 2022.07.2+576. Blood gas
110 analysis was performed using CreateTableOne::CreateContTable using default parameters.
111 Individual trajectory plots were produced using Microsoft Office Excel. The sample size was
112 calculated for achieving a balanced age and sex sample based on previously reported safety
113 and tolerability studies of ketone supplements [18]. All results are reported as mean +/-
114 standard deviation and the statistical significance cut-off was $p < 0.05$.

115

116 **RESULTS**

117 In total 24 adults were recruited and all of them finished their participation. Their
118 demographic characteristics by sex can be observed in Table 1.

119 No participant showed abnormalities in their vital signs or acid-base assessments in
120 any of their visits (Figure 2). Additionally, all acid-base parameters were non-significantly
121 different across all time points (Table 2). Additionally, no electrolyte abnormalities in Na, K,
122 Cl, or ionized Ca were observed (shown in the publicly available dataset).

123 Regarding tolerability and palatability, all participants responded to the self-reported
124 questionnaires at least once and had an adherence above 90%. Only 44 out of the 720 total
125 takes (6.2%) of the drink reported secondary symptoms. Of which, none of the reports
126 described the symptom as “severe”, (17/720 or 2.3%) were “moderate” and the remaining
127 (27/720 or 3.9%) were “mild” (Table 3).

128 The most reported secondary effects (19/720 or 2.6%) were gastrointestinal
129 discomfort, headache (7/720 or 1%), and loss of appetite (7/720 or 1%). The rest of the
130 reported secondary symptoms were reported <1% of the time. No participant reported more
131 than 2 secondary symptoms nor the same symptom more than twice. No correlation between
132 weight-adjusted dose and frequency of secondary symptoms was observed (Figure 3).

133

134 **DISCUSSION**

135 Hereby and as observed with other formulations [16,18], exogenous ketosis with Free
136 D-BHB was safe and well tolerated. Since Free-D-BHB has some advantages over other
137 formulations, more research on its potential clinical applications is warranted.

138 For example, ketone salts may not be suitable for patients who should restrict their
139 salt intake, such as those with heart failure or kidney disease [26]. On the other hand, the
140 ketone monoester has an alcohol precursor that could limit its use in patients with liver
141 disease and has poor palatability [3,20]. More importantly, being bio-identical, it is
142 reasonable to assume that the safety and pharmacokinetic properties of Free D-BHB are
143 comparable to the endogenously produced metabolite.

144 It is worth reminding that since Mexico City is more than 2200 meters above sea
145 level, the geometrical normal values are slightly different, and it is expected to observe lower
146 CO₂ and HCO₃ levels in healthy individuals. This difference is relevant because clinicians
147 elsewhere could incorrectly diagnose respiratory alkalosis with CO₂ values that are normal
148 for people living in Mexico City. [25] Consistently with other ketone supplement
149 formulations, even those inducing acute documented acid-base disturbances [8], the chronic
150 ingestion of Free D-BHB did not cause chronic acid-base or electrolyte alterations
151 [8,15,16,18].

152 Among the strengths of this study, we should mention that most participants were
153 healthcare workers and adherence was above 90%, making it unlikely that the low frequency
154 of adverse effects is due to lack of adherence, and the close communication with participants.
155 Moreover, since all participants consumed the same dose but have different weights a dose/kg
156 spectrum is created allowing us to see if the frequency of adverse symptoms is more frequent
157 in leaner individuals. As with other ketogenic supplements, no correlation was observed [18].

158 Furthermore, we examined a sample size that is comparable to what has been
159 examined for other commercially available ketogenic compounds. However, in contrast with
160 those studies, we were able to enlist a more diverse age and gender distribution in our study.
161 For example, Holland et al [15], who only studied individuals between the ages of 18 and 35,
162 and Stefan et al [17], focused exclusively on teenagers. This difference is particularly relevant
163 as some of the potential clinical applications of exogenous ketones like heart failure [12] or
164 cognitive decline [11] are on illnesses that are more frequent among elders.

165 Acid-base and blood electrolytes are the only markers that different types of
166 exogenous ketones have shown to induce changes on [8]. Therefore, when comparing studies
167 evaluating the safety of different exogenous ketones, it is important to consider that some of
168 the relevant markers, they measured are specific to the chemical nature of each supplement.
169 In other words, due to their alcohol content, liver enzyme measurements are relevant for
170 butanediol or the ketone ester but not for bioidentical BHB. Moreover, despite having used
171 BHB doses many times greater than the one we worked with, none of the exogenous ketone
172 supplements has been shown to induce detrimental changes in liver or kidney function tests
173 [8,10,15,16,18]. Notably, the only case where other biomarkers have been shown to change
174 after consuming a ketone supplement, are migraine patients with baseline metabolic risk
175 markers, in whom these markers (i.e. C-reactive protein, cortisol insulin and thyroid markers)
176 improved [10].

177 On the other hand, although comparable to what has been documented with other
178 forms of ketone supplementation [8,10,15,16,18], we should mention its follow-up time
179 among its limitations. Additionally, is not possible to make direct comparisons about
180 palatability between the other available ketogenic supplements, and more studies directly
181 addressing this question are required [20].

183 **CONCLUSIONS**

184 Diluted Free D-BHB was a safe and well-tolerated intervention for inducing sustained
185 exogenous ketosis. Being bio-identical, salt-free, and lacking intermediate metabolites, this
186 form of supplementation has a larger safety spectrum than salt or alcohol-based exogenous
187 ketones. More research is warranted to assess its clinical efficacy in those clinical scenarios
188 where achieving ketosis rapidly could be beneficial.

189

190

191 **DECLARATIONS**

192 **Funding:** The exogenous ketones used in our study were provided by a joint donation from
193 American Ketone LLC and MedPHA Ltd. However, the authors designed, carried out,
194 analysed all data and wrote this report independently.

195 **Data Availability Statement:** Anonymized data and analysis code are publicly available at:
196 <https://github.com/AdrianSotoM/FreeBHB>.

197 **Acknowledgements:** The authors thank the Central Laboratory staff at the National Institute
198 of Medical Sciences and Nutrition Salvador Zubiran for their invaluable support to make this
199 work possible.

200 **Conflicts of Interest:** Both authors declare they are free of any financial interests or personal
201 relationships that could have influenced their interpretation or reporting of these data.

202

203

204 **CONTRIBUTORSHIP STATEMENT**

205 LIPS recruited participants and collected data, and ASM designed the study and analysed
206 data. Both authors redacted this draft and approved the current version of the manuscript.

207

208

209 **REFERENCES**

- 210 1. Norwitz, N.G.; Jaramillo, J.G.; Clarke, K.; Soto, A. Ketotherapeutics for
211 Neurodegenerative Diseases. In *International Review of Neurobiology*; 2020.
- 212 2. Nicholas, A.P.; Soto-Mota, A.; Lambert, H.; Collins, A.L. Restricting Carbohydrates
213 and Calories in the Treatment of Type 2 Diabetes: A Systematic Review of the Effectiveness
214 of “low-Carbohydrate” Interventions with Differing Energy Levels. *J Nutr Sci* 2021, 10,
215 doi:10.1017/jns.2021.67.
- 216 3. Soto-Mota, A.; Norwitz, N.G.; Evans, R.D.; Clarke, K. Exogenous D- β -
217 Hydroxybutyrate Lowers Blood Glucose in Part by Decreasing the Availability of L-Alanine
218 for Gluconeogenesis. *Endocrinol Diabetes Metab* 2022, 5, e00300, doi:10.1002/EDM2.300.
- 219 4. Norwitz, N.G.; Hu, M.T.; Clarke, K. The Mechanisms by Which the Ketone Body D-
220 β -Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson’s Disease.
221 *Front Nutr* 2019, 6, 63, doi:10.3389/fnut.2019.00063.
- 222 5. Norwitz, N.G.; Dalai, S.S.; Palmer, C.M. Ketogenic Diet as a Metabolic Treatment for
223 Mental Illness. *Curr Opin Endocrinol Diabetes Obes* 2020, 27, 269–274,
224 doi:10.1097/MED.0000000000000564.
- 225 6. Cahill, G.F.; George, F.C. Fuel Metabolism in Starvation. *Annu Rev Nutr* 2006, 26, 1–
226 22, doi: 10.1146/annurev.nutr.26.061505.111258.
- 227 7. Feinman, R.D. ; Pogozelski, W.K.; Astrup, A.; Bernstein, R.K.; Fine, E.J.; Westman,
228 E.C.; Accurso, A.; Frassetto, L.; Gower, B.A.; McFarlane, S.I.; et al. Dietary Carbohydrate
229 Restriction as the First Approach in Diabetes Management: Critical Review and Evidence
230 Base. *Nutrition* 2015, 31, 1–13, doi: 10.1016/J.NUT.2014.06.011.

- 231 8. Stubbs, B.J.; Cox, P.J.; Evans, R.D.; Santer, P.; Miller, J.J.; Faull, O.K.; Magor-Elliott,
232 S.; Hiyama, S.; Stirling, M.; Clarke, K. On the Metabolism of Exogenous Ketones in
233 Humans. *Front Physiol* 2017, 8, 848, doi:10.3389/fphys.2017.00848.
- 234 9. Danan, A.; Westman, E.C.; Saslow, L.R.; Ede, G. The Ketogenic Diet for Refractory
235 Mental Illness: A Retrospective Analysis of 31 Inpatients. *Front Psychiatry* 2022, 13, 1421,
236 doi:10.3389/FPSYT.2022.951376/BIBTEX.
- 237 10. Gross, E.C.; Putananickal, N.; Orsini, A.-L.; Schoenen, J.; Fischer, D.; Soto-Mota, A.
238 Defining Metabolic Migraine with a Distinct Subgroup of Patients with Suboptimal
239 Inflammatory and Metabolic Markers. *Sci Rep* 2023, 13, 3787, doi:10.1038/s41598-023-
240 28499-y.
- 241 11. Myette-Côté, É.; Soto-Mota, A.; Cunnane, S.C. Ketones - Potential to Achieve Brain
242 Energy Rescue and Sustain Cognitive Health during Aging. *British Journal of Nutrition* 2021.
- 243 12. Nielsen, R.; Møller, N.; Gormsen, L.C.; Prof, A.; Lars,; Tolbod, P.; Nils, ; Hansson,
244 H.; Sorensen, J.; Hendrik, ; et al. Cardiovascular Effects of Treatment with the Ketone Body
245 3-Hydroxybutyrate in Chronic Heart Failure Patients Running Title: Nielsen et al.; Treating
246 Heart Failure with Ketones. *Circulation* 2019,
247 doi:10.1161/CIRCULATIONAHA.118.036459.
- 248 13. Soto-Mota, A.; Norwitz, N.G.; Clarke, K. Why a D-β-Hydroxybutyrate Monoester?
249 *Biochem Soc Trans* 2020, 48, 51–59, doi:10.1042/BST20190240.
- 250 14. Rojas-Morales, P.; Tapia, E.; Pedraza-Chaverri, J. β-Hydroxybutyrate: A Signaling
251 Metabolite in Starvation Response? *Cell Signal* 2016, 28, 917–923, doi:
252 10.1016/j.cellsig.2016.04.005.

- 253 15. Holland, A.M.; Qazi, A.S.; Beasley, K.N.; Bennett, H.R. Blood and Cardiovascular
254 Health Parameters after Supplementing with Ketone Salts for Six Weeks. *Journal of Insulin*
255 *Resistance* 2019, 4, 7, doi:10.4102/jir. v4i1.47.
- 256 16. Buga, A.; Kackley, M.L.; Crabtree, C.D.; Sapper, T.N.; McCabe, L.; Fell, B.;
257 LaFountain, R.A.; Hyde, P.N.; Martini, E.R.; Bowman, J.; et al. The Effects of a 6-Week
258 Controlled, Hypocaloric Ketogenic Diet, With and Without Exogenous Ketone Salts, on Body
259 Composition Responses. *Front Nutr* 2021, 8, 618520, doi:10.3389/fnut.2021.618520.
- 260 17. Stefan, M.; Sharp, M.; Gheith, R.; Lowery, R.; Wilson, J.; Caprio, M. The Effect of
261 Exogenous Beta-Hydroxybutyrate Salt Supplementation on Metrics of Safety and Health in
262 Adolescents. 2021, doi:10.3390/nu13030854.
- 263 18. Soto-Mota, A.; Vansant, H.; Evans, R.D.; Clarke, K. Safety and Tolerability of
264 Sustained Exogenous Ketosis Using Ketone Monoester Drinks for 28 Days in Healthy
265 Adults. *Regulatory Toxicology and Pharmacology* 2019, 109, 104506, doi:
266 10.1016/j.yrtph.2019.104506.
- 267 19. St-Onge, M.-P.; Jones, P.J.H. Physiological Effects of Medium-Chain Triglycerides:
268 Potential of Obesity. *Recent Advances in Nutritional Sciences* 2002, 132, 329–332.
- 269 20. Stubbs, B.J.; Cox, P.J.; Kirk, T.; Evans, R.D.; Clarke, K. Gastrointestinal Effects of
270 Exogenous Ketone Drinks Are Infrequent, Mild and Vary According to Ketone Compound
271 and Dose. *Int J Sport Nutr Exerc Metab* 2019, 1–23, doi:10.1123/ijsnem.2019-0014.
- 272 21. Torres, J.A.; Kruger, S.L.; Broderick, C.; AmaralKhagva, T.; Agrawal, S.; Dodam, J.R.;
273 Mrug, M.; Lyons, L.A.; Weimbs, T. Ketosis Ameliorates Renal Cyst Growth in Polycystic
274 Kidney Disease. *Cell Metab* 2019, 30, 1007-1023.e5, doi: 10.1016/j.cmet.2019.09.012.

- 275 22. Rojas-Morales, P.; Pedraza-Chaverri, J.; Tapia, E. Ketone Bodies for Kidney Injury
276 and Disease. *Advances in Redox Research* 2021, 2, 100009, doi:
277 10.1016/J.ARRES.2021.100009.
- 278 23. Seebach, D., Beck, A., Breitschuh, R., & Job, K. (2003). Direct Degradation Of The
279 Biopolymer Poly[(R)-3-Hydroxybutyric Acid] To (R)-3-Hydroxybutanoic Acid And Its
280 Methyl Ester. *Organic Syntheses*, 71. <https://doi.org/10.15227/orgsyn.071.0039>
- 281 24. Walkey, A.J.; Farber, H.W.; O'Donnell, C.; Cabral, H.; Eagan, J.S.; Philippides, G.J.
282 The Accuracy of the Central Venous Blood Gas for Acid-Base Monitoring.
283 <http://dx.doi.org/10.1177/0885066609356164> 2009, 25, 104–110,
284 doi:10.1177/0885066609356164.
- 285 25. Cid-Juárez, S.; Téllez-Navarrete, N.A.; Bautista-Bernal, A.; León-Gómez, P.; Salas-
286 Escamilla, I.; Gochicoa-Rangel, L.; Pérez-Padilla, R. Arterial Blood Gases in Normal
287 Subjects at 2240 Meters Above Sea Level: Impact of Age, Gender, and Body Mass Index.
288 *Clinical and Translational Investigation* 2023, 75, doi:10.24875/RIC.22000281.
- 289 26. Borlaug, B.A. Evaluation and Management of Heart Failure with Preserved Ejection
290 Fraction. *Nat Rev Cardiol* 2020, 17, 559–573.
- 291
- 292

293 **TABLES**

294 **Table 1.** Baseline characteristics of the participants.

	Women (n = 13)	Men (n = 11)
Age (years)	42.2 ± 13.7	41.5 ± 14.7
Height (m)	1.6 ± 0.04	1.77 ± 0.04
Weight (kg)	64.3 ± 8.8	78.9 ± 14.8
Dose (mg/kg)	158 ± 20.9	129.8 ± 19.2
Body Mass Index	23.9 ± 3.2	20.9 ± 6.3

295 * Data are means ± standard deviation.

296

297 **Table 2.** Acid-base analyses across all time points (arterialized values).

	Visit 1	Visit 2	Visit 3	p-value
pH	7.41 ± 0.03	7.43 ± 0.03	7.44 ± 0.03	0.19
pCO ₂	39.2 ± 4.3	38.5 ± 5.8	37 ± 4.7	0.30
HCO ₃ ⁻	24.9 ± 2.6	24.8 ± 2.3	24.4 ± 1.9	0.72

298 * Data are means ± standard deviation. Hypothesis testing used a Kruskal-Wallis Test.

299

300

301 **Table 3.** Secondary symptoms following each of the 720 administered ketone drinks.


Symptom	No of participants	Events* (mild/moderate)
Gastrointestinal discomfort	8	20/720 (10/10)
Loss of appetite	5	12/720 (9/3)
Headache	6	12/720 (8/4)

302 * Some participants recorded the same symptom more than once, so the occurrence was
303 expressed relative to 720, the total number of drinks consumed (24 x 30 drinks).

304

305 **FIGURES**


306



307

308

Figure 1. Study Workflow.




309

310

311

Figure 2. The individual trajectory of acid-base parameters across all time points. Panel A) pH. Panel B) pCO₂. Panel C) HCO₃.



312

313

314

Figure 3. Correlation between secondary symptom frequency and weight-adjusted dose.

315